ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer’s Disease

Data presented at Neuroscience 2012 Vancouver, BC — October 18, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today unveiled more promising new data regarding ANAVEX 2-73, the company’s drug candidate for the treatment and modification of Alzheimer’s disease currently in human clinical trials. The confidential status of the new ANAVEX 2-73 data has been…

Anavex Recognizes Alzheimer’s Action Day

New York, NY — September 21, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today joins the Alzheimer’s Association® in recognizing September 21st as Alzheimer’s Action Day. September is World Alzheimer’s Month.  In the United States alone, Alzheimer’s disease afflicts more than five million people and affects millions more husbands, wives, children, grandchildren, and…

Anavex Presents Compelling Data at World’s Largest Alzheimer’s Conference

Vancouver, BC — July 17, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced new and dramatic data concerning its Alzheimer’s disease treatment candidate ANAVEX 2-73 and leading Alzheimer’s treatments Aricept® (donepezil HCl) and Namenda® (memantine HCl).A clear synergic effect of ANAVEX 2-73 with Aricept® (donepezil HCl) has been demonstrated in a scientific…

Anavex to Present at Alzheimer’s Association International Conference

Vancouver, BC — July 9, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC, Canada. The ANAVEX…

Anavex Comments on President Obama’s National Plan to Fight Alzheimer’s Disease

Vancouver, BC — May 30, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on President Obama’s National Alzheimer’s Plan, which was unveiled earlier this month.  It is part of the National Alzheimer’s Project Act (NAPA), which was signed into law in January 2011. NAPA is the first-ever national plan to address Alzheimer’s disease. …